| pubmed-article:11137764 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11137764 | lifeskim:mentions | umls-concept:C0001554 | lld:lifeskim |
| pubmed-article:11137764 | lifeskim:mentions | umls-concept:C0026809 | lld:lifeskim |
| pubmed-article:11137764 | lifeskim:mentions | umls-concept:C0085828 | lld:lifeskim |
| pubmed-article:11137764 | lifeskim:mentions | umls-concept:C0023380 | lld:lifeskim |
| pubmed-article:11137764 | lifeskim:mentions | umls-concept:C0001455 | lld:lifeskim |
| pubmed-article:11137764 | lifeskim:mentions | umls-concept:C0015043 | lld:lifeskim |
| pubmed-article:11137764 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:11137764 | lifeskim:mentions | umls-concept:C0205341 | lld:lifeskim |
| pubmed-article:11137764 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
| pubmed-article:11137764 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
| pubmed-article:11137764 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
| pubmed-article:11137764 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
| pubmed-article:11137764 | lifeskim:mentions | umls-concept:C0231491 | lld:lifeskim |
| pubmed-article:11137764 | lifeskim:mentions | umls-concept:C0439596 | lld:lifeskim |
| pubmed-article:11137764 | lifeskim:mentions | umls-concept:C0950898 | lld:lifeskim |
| pubmed-article:11137764 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:11137764 | pubmed:dateCreated | 2001-1-26 | lld:pubmed |
| pubmed-article:11137764 | pubmed:abstractText | To characterize seizure-associated increases in cerebral cortical and thalamic cyclic AMP responsive element (CRE)- and activator protein 1 (AP-1) DNA-binding activities in lethargic (lh/lh) mice, a genetic model of absence seizures, we examined the effects of ethosuximide and CGP 46381 on these DNA-binding activities. Repeated administration (twice a day for 5 days) of ethosuximide (200 mg/kg) or CGP 46381 (60 mg/kg) attenuated both seizure behavior and the increased DNA-binding activities, and was more effective than a single administration of these drugs. These treatments did not affect either normal behavior or basal DNA-binding activities in non-epileptic control (+/+) mice. Gel supershift assays revealed that the increased CRE-binding activity was attributable to activation of the binding activity of CREB, and that the c-Fos-c-Jun complex was a component of the increased AP-1 DNA-binding activity. | lld:pubmed |
| pubmed-article:11137764 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11137764 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11137764 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11137764 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11137764 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11137764 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11137764 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11137764 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11137764 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11137764 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11137764 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11137764 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11137764 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11137764 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:11137764 | pubmed:issn | 0304-3940 | lld:pubmed |
| pubmed-article:11137764 | pubmed:author | pubmed-author:ItoYY | lld:pubmed |
| pubmed-article:11137764 | pubmed:author | pubmed-author:EndoHH | lld:pubmed |
| pubmed-article:11137764 | pubmed:author | pubmed-author:SaitoHH | lld:pubmed |
| pubmed-article:11137764 | pubmed:author | pubmed-author:IshigeKK | lld:pubmed |
| pubmed-article:11137764 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11137764 | pubmed:day | 19 | lld:pubmed |
| pubmed-article:11137764 | pubmed:volume | 297 | lld:pubmed |
| pubmed-article:11137764 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11137764 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11137764 | pubmed:pagination | 207-10 | lld:pubmed |
| pubmed-article:11137764 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:11137764 | pubmed:meshHeading | pubmed-meshheading:11137764... | lld:pubmed |
| pubmed-article:11137764 | pubmed:meshHeading | pubmed-meshheading:11137764... | lld:pubmed |
| pubmed-article:11137764 | pubmed:meshHeading | pubmed-meshheading:11137764... | lld:pubmed |
| pubmed-article:11137764 | pubmed:meshHeading | pubmed-meshheading:11137764... | lld:pubmed |
| pubmed-article:11137764 | pubmed:meshHeading | pubmed-meshheading:11137764... | lld:pubmed |
| pubmed-article:11137764 | pubmed:meshHeading | pubmed-meshheading:11137764... | lld:pubmed |
| pubmed-article:11137764 | pubmed:meshHeading | pubmed-meshheading:11137764... | lld:pubmed |
| pubmed-article:11137764 | pubmed:meshHeading | pubmed-meshheading:11137764... | lld:pubmed |
| pubmed-article:11137764 | pubmed:meshHeading | pubmed-meshheading:11137764... | lld:pubmed |
| pubmed-article:11137764 | pubmed:meshHeading | pubmed-meshheading:11137764... | lld:pubmed |
| pubmed-article:11137764 | pubmed:meshHeading | pubmed-meshheading:11137764... | lld:pubmed |
| pubmed-article:11137764 | pubmed:meshHeading | pubmed-meshheading:11137764... | lld:pubmed |
| pubmed-article:11137764 | pubmed:meshHeading | pubmed-meshheading:11137764... | lld:pubmed |
| pubmed-article:11137764 | pubmed:meshHeading | pubmed-meshheading:11137764... | lld:pubmed |
| pubmed-article:11137764 | pubmed:meshHeading | pubmed-meshheading:11137764... | lld:pubmed |
| pubmed-article:11137764 | pubmed:meshHeading | pubmed-meshheading:11137764... | lld:pubmed |
| pubmed-article:11137764 | pubmed:meshHeading | pubmed-meshheading:11137764... | lld:pubmed |
| pubmed-article:11137764 | pubmed:meshHeading | pubmed-meshheading:11137764... | lld:pubmed |
| pubmed-article:11137764 | pubmed:meshHeading | pubmed-meshheading:11137764... | lld:pubmed |
| pubmed-article:11137764 | pubmed:meshHeading | pubmed-meshheading:11137764... | lld:pubmed |
| pubmed-article:11137764 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11137764 | pubmed:articleTitle | Repeated administration of CGP 46381, a gamma-aminobutyric acidB antagonist, and ethosuximide suppresses seizure-associated cyclic adenosine 3'5' monophosphate response element- and activator protein-1 DNA-binding activities in lethargic (lh/lh) mice. | lld:pubmed |
| pubmed-article:11137764 | pubmed:affiliation | Department of Pharmacology, College of Pharmacy, Nihon University, 7-7-1 Narashinodai, 274-8555, Funabashi, Japan. ishigek@pha.nihon-u.ac.jp | lld:pubmed |
| pubmed-article:11137764 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11137764 | lld:pubmed |
